FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

ProHance® (Gadoteridol) Injection
Status: Discontinuation
»Therapeutic Categories: Medical Imaging

Expand all

Bracco Diagnostics (New 06/01/2021)

Company Contact Information:
877-272-2269

Presentation Posting Date Related Information
279.3 mg/mL, 5 x 10 mL pre-filled syringe, (NDC 0270-1111-16) 06/01/2021 Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM bottles. All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70
279.3 mg/mL, 5 x 17 mL pre-filled syringe, (NDC 0270-111-45) 06/01/2021 Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM bottles. All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English